Key facts
- This page summarizes Philippe Calais's Form 3 filing for Transcode Therapeutics, Inc. (RNAZ).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Jul 2021, 21:53.
Philippe Calais - 08 Jul 2021 Form 3 Insider Report for Transcode Therapeutics, Inc. (RNAZ)
- Reporting relationship
- Director
- Issuer ticker
- RNAZ
- Reported as of
- 08 Jul 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 08 Jul 2021, 21:53:05 UTC
- Next SEC filing
- 22 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas A. Fitzgerald, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Philippe Calais filed Form 3 for Transcode Therapeutics, Inc. (RNAZ) on 08 Jul 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RNAZ
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 127,377
- Date
- 08 Jul 2021
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RNAZ
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 08 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 36,393
- Exercise price
- $3.91
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the first anniversary of the Vesting Commencement Date (December 1, 2020), provided that the Optionee continues to have a Service Relationship with the Company at such time. Thereafter, the remaining sixty-seven percent (67%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Optionee continues to have a Service Relationship with the Company on each vesting date.
SEC remarks
Exhibit 24: Power of Attorney